Sheets Smith Investment Management’s Cardiol Therapeutics CRDL Stock Holding History

Sheets Smith Investment Management’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$152K	Buy	+142,097	New	+$172K	0.1%	129

Other funds holding CRDL

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Sheets Smith Investment Management's CRDL Position: Q3 2025 in Review

Sheets Smith Investment Management opened a new position in Cardiol Therapeutics (CRDL) in Q3 2025: 142,097 shares worth $152K. The stake represents 0.1% of the portfolio and ranks #129 among its holdings.

48 funds tracked by Wall St. Rank hold CRDL as of Q3 2025.

Sheets Smith Investment Management held 142,097 shares of Cardiol Therapeutics worth $152K as of Q3 2025.
Cardiol Therapeutics was a new Sheets Smith Investment Management position in Q3 2025.
Cardiol Therapeutics made up 0.1% of Sheets Smith Investment Management's portfolio in Q3 2025, its #129 holding.
48 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2025.

Based on Sheets Smith Investment Management's 13F filing for Q3 2025, filed 8 Oct 2025.